G1 Therapeutics is enrolling a clinical trial in SCLC.

Study 03 - For patients previously treated with chemotherapy.

Study 03 is for patients diagnosed with SCLC who have already received chemotherapy. For these subjects (a person that has volunteered to participate in a research study), the investigational medicine or placebo will be administered just prior to topotecan chemotherapy.

The study is enrolling in the phase 2 randomized portion of the study, and approximately 130 subjects will be enrolled.